STTR Phase I: Development of Bacterial Glycorandomization Hosts

STTR 第一阶段：细菌糖随机化宿主的开发

• 批准号: 0740027
• 负责人: James Prudent
• 金额: $ 15万
• 依托单位: centrose llc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0740027&HistoricalAwards=false
• 关键词: STTR; Phase; Development; Bacterial; Glycorandomization

This Small Business Technology Transfer Research Phase I project develops methodology needed for the production of sugar enhanced (glycosidic) compound libraries and final therapeutic leads. Sugar attachments have been identified as a powerful way to make therapeutically relevant small molecules. Examples of drugs with sugar attachments such as erythromycin and doxorubicin show how sugars can change inactive molecules into antibacterial or anticancer drugs. Finding the correct genetically altered cell-based systems needed for efficient high yield production of small molecule sugar enhanced compounds is the first phase at exploiting sugar enhanced drug discovery beyond what Nature has provided.The broader impacts of this research are found in the enormous potential that sugar enhancement provides to therapeutics. Sugars are critical molecules that regulate a vast array of biological processes and pathways in the human body and play fundamental roles in diseases as well as in drug action. This project will greatly expand the ease and reduce the cost of making, screening and commercially scaling sugar-enhanced small molecule therapeutics.

这个小企业技术转让研究第一阶段项目开发生产糖增强（糖苷）化合物库和最终治疗线索所需的方法。糖连接已被确定为制造治疗相关小分子的有效方法。红霉素和多柔比星等带有糖连接物的药物的例子显示了糖如何将非活性分子转化为抗菌或抗癌药物。找到正确的基因改变的细胞为基础的系统所需的高效高产生产的小分子糖增强化合物是第一阶段在利用糖增强药物发现超出了自然提供了这项研究的更广泛的影响是发现的巨大潜力，糖增强提供给治疗。糖是调节人体内大量生物过程和途径的关键分子，在疾病和药物作用中发挥重要作用。该项目将极大地扩大糖增强小分子治疗剂的制造、筛选和商业规模化的便利性并降低其成本。